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Abstract
Objective:  Triggered  by  the  growing  knowledge  on  the  link  between  the  intestinal  microbiome
and human  health,  the  interest  in  probiotics  is  ever  increasing.  The  authors  aimed  to  review  the
recent  literature  on  probiotics,  from  deﬁnitions  to  clinical  beneﬁts,  with  emphasis  on  children.
Sources:  Relevant  literature  from  searches  of  PubMed,  CINAHL,  and  recent  consensus  state-
ments were  reviewed.
Summary of  the  ﬁndings: While  a  balanced  microbiome  is  related  to  health,  an  imbalanced
microbiome  or  dysbiosis  is  related  to  many  health  problems  both  within  the  gastro-intestinal
tract, such  as  diarrhea  and  inﬂammatory  bowel  disease,  and  outside  the  gastro-intestinal  tract
such  as  obesity  and  allergy.  In  this  context,  a  strict  regulation  of  probiotics  with  health  claims  is
urgent,  because  the  vast  majority  of  these  products  are  commercialized  as  food  (supplements),
claiming  health  beneﬁts  that  are  often  not  substantiated  with  clinically  relevant  evidence.
The  major  indications  of  probiotics  are  in  the  area  of  the  prevention  and  treatment  of  gastro-
intestinal  related  disorders,  but  more  data  has  become  available  on  extra-intestinal  indications.
At  least  two  published  randomized  controlled  trials  with  the  commercialized  probiotic  product
in  the  claimed  indication  are  a  minimal  condition  before  a  claim  can  be  sustained.  Today,
Lactobacillus  rhamnosus  GG  and  Saccharomyces  boulardii  are  the  best-studied  strains.  Although
adverse  effects  have  sporadically  been  reported,  these  probiotics  can  be  considered  as  safe.
Conclusions:  Although  regulation  is  improving,  more  stringent  deﬁnitions  are  still  required.
Evidence of  clinical  beneﬁt  is  accumulating,  although  still  missing  in  many  areas.  Misuse  and
use  of  products  that  have  not  been  validated  constitute  potential  drawbacks.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.   Please cite this article as: Vandenplas Y, Huys G, Daube G. Probiotics: an update. J Pediatr (Rio J). 2015;91:6--21.
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Probióticos:  informac¸ões  atualizadas
Resumo
Objetivo:  Motivado  pelo  conhecimento  cada  vez  maior  da  associac¸ão  entre  o  microbioma
intestinal e  a  saúde  humana,  o  interesse  nos  probióticos  vem  crescendo  cada  vez  mais.  Os
autores  visaram  analisar  a  última  literatura  a  respeito  dos  probióticos,  de  deﬁnic¸ões  a  benefícios
clínicos  com  ênfase  nas  crianc¸as.
Fontes dos  dados: Foi  analisada  a  literatura  relevante  de  pesquisas  do  PubMed,  do  CINAHL  e
dos últimos  consensos.
Síntese dos  dados:  Apesar  de  um  equilíbrio  no  microbioma  estar  relacionado  à  saúde,  um
desequilíbrio no  microbioma  ou  disbiose  está  relacionado  a  vários  problemas  de  saúde  no  trato
gastrointestinal,  como  diarreia  e  doenc¸a inﬂamatória  intestinal,  e  fora  do  trato  gastrointesti-
nal,  como  obesidade  e  alergia.  Nesse  contexto,  a  regulamentac¸ão  rigorosa  dos  probióticos  a
alegac¸ões  de  saúde  é  urgente,  pois  a  grande  maioria  desses  produtos  é  comercializada  como
alimentac¸ão  (suplementos),  alegando  benefícios  à  saúde  que  frequentemente  não  são  com-
provados  com  evidências  clinicamente  relevantes.  As  principais  indicac¸ões  de  probióticos  são
feitas  na  área  da  prevenc¸ão  e  tratamento  de  doenc¸as  gastrointestinais,  porém  mais  dados  têm
sido  disponibilizados  a  respeito  de  indicac¸ões  extraintestinais.  Pelo  menos  dois  ensaios  clínicos
controlados  e  randomizados  publicados  com  o  probiótico  comercializado  na  indicac¸ão  declarada
são  a  condic¸ão  mínima  antes  de  uma  aﬁrmac¸ão  poder  ser  mantida.  Atualmente,  o  Lactobacillus
rhamnosus  GG  e  Saccharomyces  boulardii  são  as  melhores  cepas  estudadas.  Apesar  de  efeitos
adversos  terem  sido  esporadicamente  relatados,  os  probióticos  podem  ser  considerados  seguros.
Conclusões:  Apesar  de  a  regulamentac¸ão  estar  aumentando,  ainda  são  necessárias  deﬁnic¸ões
mais rigorosas.  As  evidências  de  benefícios  clínicos  estão  aumentando,  apesar  de  ainda  ausentes
em  várias  áreas.  O  uso  inadequado  e  a  utilizac¸ão  de  produtos  não  validados  constituem  possíveis
desvantagens.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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The  joint  Food  and  Agriculture  Organization  (FAO)  and  World
Health Organization  (WHO)  Expert  Consultation  on  evalua-
tion of  health  and  nutritional  properties  of  probiotics  in  food
including powder  milk  with  live  lactic  acid  bacteria  deﬁned
probiotics as:  ‘‘live  microorganisms  that,  when  adminis-
tered in  adequate  amounts,  confer  a  health  beneﬁt  on  the
host’’.1 In  2002,  a  joint  FAO/WHO  Working  Group2 released
guidelines for  the  evaluation  of  probiotics  in  food.  The  min-
imum requirements  needed  for  probiotic  status  include:
-  assessment  of  strain  identity  (genus,  species,  strain  level);
- in  vitro  tests  to  screen  potential  probiotics:  e.g.  resis-
tance  to  gastric  acidity,  bile  acid,  and  digestive  enzymes,
antimicrobial  activity  against  potentially  pathogenic
bacteria;
- safety  assessment:  requirements  for  proof  that  a  probiotic
strain  is  safe  and  without  contamination  in  its  delivery
form;
- in  vivo  studies  for  substantiation  of  the  health  effects  in
the  target  host.Following the  FAO/WHO  deﬁnition,  the  International  Life
Science Institute  (ILSI)3 and  the  European  Food  and  Feed
Cultures Association  (EFFCA)4 have  released  similar  deﬁni-
tions for  a  probiotic:  ‘‘a  live  microbial  food  ingredient  that,
o
s
b
dhen  consumed  in  adequate  amounts,  confers  health  bene-
ts on  the  consumers’’  and  ‘‘live  microorganisms  that,  when
ngested or  locally  applied  in  sufﬁcient  numbers,  provide  the
onsumer with  one  or  more  proven  health  beneﬁts’’.  These
eﬁnitions de  facto  imply  that  probiotic  ingestion  provides
eneﬁts for  host  health.
The  science  related  to  probiotics  is  recent,  and  is  thus
n constant  evolution.  Probiotics  used  in  food,  supplied  as
ietary supplement,  or  as  active  components  of  a  registered
edication, should  not  only  be  capable  of  surviving  passage
hrough the  digestive  tract  by  exhibiting  acid  and  bile  sur-
ival, but  should  also  have  the  capability  to  proliferate  in
he gut.  Probiotics  must  be  able  to  exert  their  beneﬁts  on
he host  through  growth  and/or  activity  in  the  human  body.
opical or  local  application  of  probiotics  is  also  proposed  in
iew of  the  recent  evolution  of  scientiﬁc  data.  Therefore,
he ability  to  remain  viable  and  effective  at  the  target  site
hould be  studied  and  conﬁrmed  for  each  strain,  or  even
etter, for  each  commercialized  product.  Clinical  studies
hould be  performed  with  the  commercialized  product  and
ot with  the  isolated  strain.  However,  lack  of  protection  con-
ributes to  the  fact  that  some  companies  refuse  to  deliver
nformation on  the  speciﬁc  strains  in  their  product.5 Recent
iterature has  demonstrated  that  one  of  the  mechanisms
f action  of  probiotics  involves  stimulation  of  the  immune
ystem. It  is  questionable  whether  the  probiotics  need  to
e ‘‘alive’’  to  induce  immune-modulation.  Therefore,  the
eﬁnition may  have  to  be  revised  in  the  future.
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According  to  the  European  Union  (EU),  health  claims
hould only  be  authorized  for  use  in  the  EU  after  a  scien-
iﬁc assessment  of  the  highest  possible  standard  has  been
arried out  by  the  Panel  on  Dietetic  Products,  Nutrition,  and
llergies (NDA)  of  the  European  Food  Safety  Authority  (EFSA)
Regulation (EC)  N  1924/2006].6 The  key  questions  that  were
ddressed  by  the  EFSA  NDA  panel  are:
 Is  the  food/constituent  sufﬁciently  deﬁned  and  characte-
rized?
 Is  the  claimed  effect  sufﬁciently  deﬁned,  and  is  it  a  ben-
eﬁcial  physiological  effect?
 Have  pertinent  human  studies  been  presented  to  substan-
tiate  the  claim?
The EFSA  recommendations  are  an  important  step  for-
ard in  trying  to  bring  claims  for  probiotic  food  supplements
nd medication  closer  together.  However,  companies  discov-
red  side-ways  to  avoid  EFSA  restrictions.  Some  of  the  food
upplements are  in  the  process  of  registration  as  ‘‘medical
evice’’, for  which  claims  can  be  made  without  providing
ard scientiﬁc  evidence.  Moreover,  production  require-
ents on  quality  control  and  safety  still  differ  substantially
etween food  supplements  and  medication,  putting  medi-
ation in  a  disadvantageous  situation.
Ofﬁcial  controls  by  national  authorities  are  performed
o ensure  compliance  with  food  law.  Apart  from  the  risk  of
sing unauthorized  strains,  product  mislabeling  is  a  known
roblem, partly  due  to  the  use  of  phenotyping  or  genotyp-
ng methods  that  lack  discriminative  power.7 In  addition  to
fﬁcial controls,  private  controls  by  food  producing  compa-
ies are  important  in  the  context  of  protection  of  patented
trains and  industrial  property  rights.
In  their  ‘Guidelines  for  the  Evaluation  of  Probiotics  in
ood’, the  FAO/WHO  Working  Group2 recommends  that  the
ollowing information  should  be  described  on  the  label  of
robiotic products:
 Genus,  species,  and  strain  designation.  Strain  designation
should  not  mislead  consumers  regarding  the  functionality
of  the  strain;
 Minimum  viable  numbers  of  each  probiotic  strain  at  the
end  of  the  shelf-life;
 Suggested  serving  size,  which  must  deliver  the  effective
dose  of  probiotics  related  to  the  health  claim;
 Health  claim(s);
 Proper  storage  conditions;
 Corporate  contact  details  for  consumer  information.
In  most  countries,  only  general  health  claims  are  cur-
ently allowed  on  foods  containing  probiotics.  The  FAO/WHO
orking Group2 recommended  that  speciﬁc  health  claims  on
oods should  be  allowed  relating  to  the  use  of  probiotics,
henever sufﬁcient  scientiﬁc  evidence  is  available.  Such
peciﬁc health  claims  should  be  permitted  on  the  label  and
n promotional  material.  For  example,  a  speciﬁc  claim  stat-
ng that  a  probiotic  ‘reduces  the  incidence  and  severity  of
otavirus diarrhea  in  infants’  would  be  more  informative  to
he consumer  than  a  general  claim  that  states  ‘improves  gut
ealth’.  The  recommendation  is  that  the  product  manufac-
urer should  be  responsible  for  conducting  an  independent
P
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hird  party  review  by  scientiﬁc  experts  in  order  to  establish
he truthfulness  of  the  health  claims.
In  line  with  the  suggestions  of  the  FAO/WHO  Working
roup,2 on  December  20,  2006,  the  European  Parliament
nd the  Council  published  a  new  regulation  (No.  1924/2006)
egarding ‘‘Nutrition  and  Health  Claims  Made  on  Foods’’.6
his  regulation  applies  to  all  nutritional  and  health  claims
elating to  all  types  of  food  intended  for  ﬁnal  consumers;
hus including  probiotic  products  brought  to  the  market  with
 health  claim.  The  regulation  aims  to  consolidate  the  nutri-
ion and  health  claims  at  European  level  in  order  to  better
rotect consumers,  including  commercial  communications
labeling, presentation,  and  promotional  campaigns),  as
ell as  trademarks  and  other  brand  names  that  could  be
onstrued as  nutrition  or  health  claims.
unctional effects of probiotics
he  deﬁnition  ‘‘probiotics  are  live  microorganisms  which
hen administered  in  adequate  amounts  confer  a  health
eneﬁt on  the  host’’  only  generalizes  the  probiotic  func-
ionality as  conferring  a health  beneﬁt  to  the  host.  Hence,
his deﬁnition  entails  that  there  must  be  a  measurable  phys-
ological beneﬁt  to  the  host  who  uses  the  probiotic  product.
n addition,  it  is  not  speciﬁed  that  the  probiotic  strain
ust be  provided  through  oral  delivery,  nor  are  there  spe-
iﬁc requirements  regarding  the  mode  of  action.  The  latter
lso implies  that  survival  of  the  probiotic  microorganisms
hroughout the  gastrointestinal  (GI)  tract  is  not  a  prerequi-
ite for  recognition  of  probiotic  effects.  For  example,  the
elivery of  lactase  through  administration  of  live  Strepto-
occus thermophilus  to  the  small  intestine  can  be  considered
s a  probiotic  activity,  although  the  bacterial  strain  itself
oes not  survive  the  digestive  tract.8
When  considering  probiotic  functionality,  the  abovemen-
ioned deﬁnition  of  probiotics  is  to  be  interpreted  in  a  very
road way.  This  broad  functionality  deﬁnition  complicates
he process  of  functional  characterization  of  probiotics.  The
se of  probiotics  may  target  several  body  sites  (mouth,  GI
ract, respiratory  tract,  urinary  tract,  skin,  vagina,  etc),
nd its  application  can  also  target  speciﬁc  human  subpop-
lations: healthy  individuals,  children,  elderly,  ill  subjects,
nd immunecompromised  and  genetically  predisposed  indi-
iduals,  among  others.  There  is  an  extremely  diverse  range
f potential  biological  effects,  and  new  functional  activi-
ies are  constantly  being  explored.  While  some  models  are
erfectly suited  for  studying  the  colonization  potency  of
robiotics, other  models  need  to  be  applied  for  assessing
heir immune-modulating  potential,  their  resilience  against
athogen invasion  of  the  GI  tract,  or  their  anti-inﬂammatory
roperties.
unctional characterization of probiotics
arget  sitesrobiotic  products  have  been  developed  to  improve  physio-
ogical conditions  at  different  body  sites.  While  the  GI  tract
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is  the  most  important  target  for  the  majority  of  probiotic
applications, other  body  sites,  such  as  the  mouth,  the  uro-
genital tract,  and  the  skin,  are  also  considered.  Probiotics
may play  an  important  in  oral  medicine  and  dentistry.9,10
Probiotics  are  also  considered  for  controlling  and  pre-
venting infections  of  the  reproductive  and  urinary  tract.11--14
Regarding  skin  applications,  probiotics  may  be  consumed
orally to  induce  an  immune  response  that  has  systemic
effects, e.g.,  for  controlling  skin  inﬂammation15 and  der-
matological diseases  in  general.16 Probiotics  have  also
been used  as  protection  against  respiratory  tract  infec-
tions. Lactobacillus  (L.)  rhamnosus  GG  prevents  respiratory
tract infections  in  addition  to  the  conventional  protection
against GI  infections.17 There  is  a  plethora  of  probiotic
strains and  applications  available  with  the  GI  tract  as  tar-
get site.  Such  applications  aim  at  several  health  beneﬁts,
such as  decreasing  pathogen  colonization,  improving  vitamin
synthesis, optimizing  intestinal  transit,  alleviating  lactose
intolerance, reducing  bloating,  and  promoting  immune-
modulatory effects,  among  others.
Delivery  mode
In  order  to  provide  health  beneﬁts,  probiotic  strains  often
require a  speciﬁc  matrix  to  guarantee  optimal  strain  survival
along the  GI  tract.  For  instance,  probiotics  have  recently
been formulated  in  a  chocolate  matrix,  which  resulted  in  a
more optimal  survival  of  the  probiotic  strains  in  comparison
with conventional  probiotic  formulation  methods.18 Other
methods include  the  introduction  of  probiotics  in  more  con-
ventional products  such  as  milk,19 keﬁr,20 and  yoghurts,  or
in more  speciﬁc  matrices  such  as  cereals,  cheese,  sausages,
and cookies.  Obviously,  many  probiotics  are  introduced  for
commercial reasons,  to  obtain  a  better  product  placement
or to  integrate  the  probiotic  market  (common  examples  are
fruit juices,  ice  creams,  candies,  granola  bars,  etc).
Besides  the  incorporation  of  probiotics  in  food  prod-
ucts, probiotic  strains  are  also  provided  as  food  supplement,
often targeting  speciﬁc  health  problems.  Probiotic  food
supplements (e.g.  L.  rhamnosus  GG,  L.  reuteri)  and  med-
ication (e.g.  Saccharomyces  boulardii)  have  almost  become
standard in  the  treatment  of  pediatric  gastroenteritis.  There
are many  infant  formulas  with  probiotics,  both  to  prevent
and alleviate  diarrhea.
L. lactis  strains  that  secrete  IL-10  or  immunomodula-
tory Yersinia  LcrV  protein  were  developed  to  treat  colitis
in mouse  models.21,22 Such  approach  is  currently  being  con-
sidered for  the  treatment  of  oral  mucositis  (high  incidence
in head/neck  cancer  patients  receiving  radiotherapy)  with  a
human trefoil  factor  1-secreting  L.  lactis.  A  molecular  basis
of the  therapeutic  applications  and  the  chemopreventive
activities of  certain  probiotic  metabolites,  with  emphasis  on
the interaction  between  these  metabolites  and  the  molec-
ular signaling  cascades,  are  considered  to  be  epigenetic
targets in  preventing  colon  cancer.23
Finally,  probiotic  delivery  not  only  pertains  the  food  or
pharmaceutical environment  in  which  the  probiotic  is  for-
mulated. Speciﬁc  ointments  and  nasal  sprays  have  been
developed;24 currently,  even  the  introduction  of  probiotics
in mattresses  and  cleaning  agents  is  gaining  momentum  for
l
h
a
s9
n  optimized  hygienic  control.  The  latter  illustrates  the
eed to  broaden  the  control  on  claims  larger  than  food
upplements and  food.  If  the  EU  installs  authorities,  such
s the  EFSA,  to  control  claims  for  foods  and  food  supple-
ents, health-claims  for  non-food  related  products  should
e equally  controlled.
train  survival
n  many  cases,  health  beneﬁts  are  only  obtained  when  a  pro-
iotic strain  reaches  the  target  site  in  a  metabolically  active
tate and  in  sufﬁcient  numbers.  For  oral  delivery,  probiotic
icroorganisms must  survive  the  different  physicochemical,
nzymatic, and  microbial  stresses  throughout  the  GI  transit.
Firstly,  microorganisms  have  to  cross  the  acidic  envi-
onment from  the  stomach.  In  addition,  the  absence  or
resence of  a  food  matrix  signiﬁcantly  determines  the  pH
roﬁle to  which  the  probiotic  strain  is  subjected.  While  the
nitial pH  buffering  effect  from  food  may  subject  the  pro-
iotic strain  to  initially  less  stringent  acidic  conditions,  a
onger digestion  time  in  the  stomach  under  fed  conditions
ay expose  part  of  the  dosed  probiotic  to  acidic  conditions
or a  longer  time.  Many  probiotic  microorganisms  have  been
elected for  their  higher  resilience  in  such  conditions,  and
ew methodologies  are  available  to  allow  encapsulation  of
robiotic strains  in  that  purpose.25
A  second  stress  component  is  the  presence  of  bile
alts that  elicit  membrane-compromising  properties  towards
icroorganisms, due  to  their  amphiphilic  character.  A  par-
icular functional  characteristic  of  microorganisms  is  their
bility to  deal  with  bile  salt  stress  via  bile  salt  hydrolase.
ile salt  hydrolase  bacteria  typically  cleave  the  glycin  or  tau-
in moiety  from  conjugated  bile  salts,  rendering  the  latter
ess bacteriostatic.  This  feature  is  of  particular  importance
o optimize  strain  survival  during  intestinal  transit  and  has
een proposed  as  a  mechanism  to  explain  how  probiotics
ould lower  serum  cholesterol  levels.26
Another  feature  of  probiotic  strain  survival  is  the  abil-
ty to  colonize  the  GI  tract.  This  property  can  be  divided
nto an  ecological  component  and  a  mucosal  component.
irstly, once  a  probiotic  organism  has  survived  gastric  acid
nd duodenal  bile  salts  and  thus  reaches  the  ileum  and
olon, it  has  the  possibility  to  develop  in  a  less  stringent
nvironment. Yet,  it  reaches  an  environment  with  a  highly
igniﬁcant microbial  background  --  the  ileum  and  colon
eaching bacterial  concentrations  of  107 and  1011 cells/mL
hyme, respectively.  Obviously,  a  probiotic  strain  can  be
onsidered as  foreign  to  the  residing  endogenous  micro-
iota, and  unless  speciﬁc  nutrients  are  provided  for  the
robiotic in  the  product  formulation  (e.g.  synbiotic),  the
train must  compete  with  the  residing  microbial  community
or available  substrates.  In  ecological  terms,  the  dosed  pro-
iotic must  occupy  a  functional  niche  in  the  gut  microbial
cosystem. Secondly,  an  important  property  for  probiotics,
.g. with  respect  to  pathogen  control,  is  its  ability  to  adhere
o and  thrive  in  the  mucus  surface  that  covers  the  gut  epithe-
ium. Mucosal  adhesion  can  rely  on  cell  wall  properties.  The
ydrophobic nature  of  microbial  strains  can  be  assessed  with
 straightforward  BATH  assay,27 while  a  speciﬁc  mucus  adhe-
ion can  be  measured  using  short  term  adhesion  assays  with
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ut-derived  mucins  (mostly  from  animal  origin).27,28 How-
ver, the  aspeciﬁc  adhesion  of  gut  microorganisms  to  gut
ucins is  only  sufﬁcient  for  microcolony  formation,  and  does
ot guarantee  a  prolonged  colonization  of  the  mucus  layer.  It
as been  well  described  that  speciﬁc  microorganisms  modu-
ate their  gene  expression  following  their  incorporation  into
he mucosal  surface.  This  has  not  only  been  described  for
athogens,28,29 but  also  for  probiotic  microorganisms,  such
s L.  rhamnosus  GG,  which  may  upregulate  the  formation  of
peciﬁc pili  in  the  mucosal  environment.30
uman  target  groups
robiotic  products  have  been  developed  for  a  wide  variety
f health  claims.  Probiotics  can  target  both  healthy  and  ill
ndividuals. The  expected  effects  can  be  of  a  preventive  or
urative nature.  The  goal  can  be  to  ﬁght  the  cause  of  the
isease or  metabolic  alterations,  or  to  lessen  the  symptoms
ssociated with  the  occurrence  or  progression  of  a  disease
r metabolic  alteration.
With the  aim  of  improving  health  in  the  human  body,
he intake  of  a  probiotic  strain  by  healthy  subjects  has
rimarily preventive  objectives.  Yet,  it  must  be  empha-
ized that  the  introduction  of  a  foreign  strain  --  even  if  it
s a  probiotic  --  must  be  approached  with  care  and  must
e performed  after  a  well-considered  evaluation  process.
articularly, the  gut  environment  from  sensitive  human  sub-
opulations, such  as  infants  and  toddlers,  undergoes  a  high
egree of  development  or  transition.  Many  studies  on  pro-
iotic applications  reported  a  positive  outcome  in  markers
hat can  be  of  relevance  for  human  health.  Probiotic  studies
ave shown  beneﬁcial  effects  in  all  age-related  subgroups,
uch as  mother-infant  pairs,  preterm  infants,  newborns,
nfants, older  children,  and  elderly  people.
For  example,  fermented  milk  drinks  with  L.  casei  strain
hirota positively  stimulate  the  immune  system  in  healthy
uman subjects.31 With  respect  to  different  age  groups,
he effects  from  long  term  consumption  of  probiotic  milk
n infections  was  evaluated  in  children  attending  day  care
enters,32 while  L.  delbrueckii  subsp.  bulgaricus  OLL1073R-
 was  given  to  elderly  persons  with  the  aim  of  reducing  the
isk of  infection.33
In  case  the  microbial  community  from  a  speciﬁc  body
egion is  disturbed,  leading  to  the  so-called  dysbiosis,  func-
ional niches  become  available  in  the  ecosystem.  Examples
f dysbiosis  are  the  changes  in  microbial  ecosystem  in  the
outh associated  with  dental  caries,  or  dysbiosis  associ-
ted with  bacterial  vaginosis.  Twetman  recently  reviewed
he effects  from  probiotics  on  oral  health  in  children.34
or  example,  long-term  application  of  probiotic  strains  such
s L.  rhamnosus  GG  lowered  the  risk  of  dental  caries  in
hildren;35 the  importance  of  probiotic  supplementation
uring orthodontic  therapy  was  also  reported.36 Similarly,
icrobial dysbiosis  in  the  urogenital  tract,  particularly  bac-
erial  vaginosis,  can  also  be  treated  with  probiotics.37 L.
hamnosus GG  and  speciﬁc  L.  acidophilus  strains  have  been
sed to  treat  bacterial  vaginosis.38,39 Probiotics  may  also  be
pplied orally  to  reduce  health  risks  that  originate  from
he gut  environment.  Helicobacter  pylori-colonized  sub-
ects have  been  treated  with  L.  casei  milk  drinks40 and
v
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.  gasseri  OLL2716  (LG21),41 while  speciﬁc  Biﬁdobacterium
trains display  anti-Helicobacter  effects  through  the  pro-
uction of  antimicrobial  peptides.42 However,  there  is  proof
hat dysbiosis  occurs  in  Crohn’s  disease  (either  as  cause
r consequence),  but  probiotic  supplementation  has  always
ailed to  prevent  relapse,  except  in  pouchitis.  In  addition,
here is  speciﬁc  attention  for  developing  probiotic  concepts
or children  under  modiﬁed  risks.  Preterm  infants  display
n increased  risk  for  developing  necrotizing  enterocolitis,
hich is  decreased  by  the  application  of  oral  probiotics.43
asis of the biological effect of probiotics
he  health  beneﬁts  from  probiotic  products  and  applications
re extremely  diverse  and  are  continuously  expanded  with
ew insights  and  scientiﬁc  developments.
icrobiological  functionality
he  ultimate  goals  of  microbiological  interventions  through
robiotics may  be  to  stabilize  or  improve  microbial  homeo-
tasis in  a  body  environment  and  to  lower  pathogen  invasion
nd colonization.  The  resilience  of  a  microbial  community
gainst invasion  by  exogenous  strains  largely  depends  on
he availability  of  non-occupied  functional  niches.  If  not  all
unctional niches  are  occupied  by  the  endogenous  microbial
ommunity, there  is  an  increased  risk  for  pathogen  invasion
n the  ecosystem,  colonization,  and  subsequent  infection.
Probiotic  microorganisms  can  be  used  to  improve  or
estore microbial  homeostasis  in  two  scenarios.  Firstly,  they
ay occupy  functional  niches  that  are  left  open  by  the
ndogenous community,  thereby  preventing  (opportunis-
ic) pathogens  from  occupying  that  niche.  Such  process  is
ften referred  to  as  competitive  exclusion,  and  primar-
ly targets  the  competition  for  nutrients,  physical  sites
e.g. mucus  adhesion)  or  receptors.  The  second  scenario  is
ore of  an  antagonistic  nature  as  probiotics  may  actively
ower (opportunistic)  pathogen  invasion  or  development
nto the  ecosystem.  Such  approach  primarily  targets:  i)  the
roduction of  short  chain  fatty  acids  and  other  organic
cids (e.g.  lactic  acid)  by  probiotics,  thereby  lowering
he pH  and  increasing  the  bacteriostatic  effect  of  organic
cids towards  pathogens;  ii)  the  production  of  bacteri-
cins, which  are  small  microbial  peptides  with  bacteriostatic
r bactericidal  activity;  and  iii)  the  production  of  reac-
ive oxygen  species,  such  as  hydrogen  peroxide,  that  are
ighly reactive  and  increase  oxidative  stress  for  pathogens
n micro-environments.
utritional  functionality
peciﬁc  microbial  groups  produce  vitamins  and  may  thereby
ontribute to  vitamin  availability  to  the  human  host.  Apart
rom vitamin  K,44 vitamin  B12,45 and  pyridoxine,46 other
itamins, such  as  biotin,  folate,  nicotinic  acid,  and  thi-
mine, can  be  produced  by  gut  microorganisms.  This  type
f activities  may  affect  host  health  and  may  therefore  be
onsidered as  potential  probiotic  effects.
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Lactase  deﬁciency  causes  lactose  intolerance,  which
results in  abdominal  cramping,  nausea,  and  bloating.  Probio-
tic strains  that  are  lactase-positive  have  been  successfully
applied to  relieve  discomfort  from  lactose  intolerance.47
Other  nutritional  functionalities  may  include  the  pro-
duction of  health-promoting  compounds.  The  metabolic
potency of  gut  microorganisms  is  enormous  and  may
rival or  even  exceed  that  of  the  liver.48 The  gut  envi-
ronment harbors  several  small  chemical  factories  that
produce numerous  chemical  components  with  putative
health-modulating effects.49 Isolated  strains  that  produce
health-promoting products  may  also  be  considered  as  hav-
ing probiotic  potential.  For  instance,  the  production  of
health-promoting conjugated  linoleic  acids  (CLA)  has  been
reported for  Biﬁdobacterium  strains,50 L.  plantarum  JCM
1551,51 and  speciﬁc  L.  acidophilus  strains.  Also,  conver-
sion of  phytoestrogen  precursors  to  bioactive  metabolites
by supplemented  microorganisms  is  a  potential  pathway  for
future probiotic  applications.  For  example,  Decroos  et  al.
previously isolated  a  microbial  consortium  that  converts
soy-derived daidzein  into  the  bioactive  equol,52 while  Pos-
semiers et  al.  performed  an  in  vitro  investigation  of  the
probiotic potential  of  Eubacterium  limosum  strains  to  con-
vert hop  isoxanthohumol  into  8-prenylnaringenin.53
Physiological  functionality
Probiotic  microorganisms  have  been  reported  to  enhance
GI transit.  Hamilton-Miller  previously  reviewed  such  func-
tionality for  the  application  of  probiotic  products  in  elderly
persons.54 Other  potential  physiological  effects  may  include
the reduction  by  probiotics  of  bloating  or  gas  production,
the enhancement  of  ion  absorption  by  intestinal  epithelial
cells55 and  the  decrease  of  bile  salt  toxicity  or  the  decrease
of serum  cholesterol  levels  by  bile  salt  hydrolase  positive
probiotics.56,57
Lowering  health  detrimental  components  in  the  gut
Probiotic  microorganisms  are  also  applied  to  reduce  the
health risks  from  hazardous  components.  For  example,  oral
exposure  to  contaminants,  either  from  a  food  matrix  or
from an  environmental  matrix  (soil,  dust,  water)  is  the  most
dominant scenario  by  which  the  human  body  gets  internally
exposed to  contaminants.  These  can  be:  i)  mycotoxins,  pro-
duced from  fungi  on  a  wide  variety  of  crops,  cereals  in
particular; ii)  xenobiotics  with  toxic  properties  as  unwanted
residues from  environmental  contamination  of  the  food
chain; or  iii)  hazardous  compounds  from  the  food  produc-
tion process  as  such  (e.g.  PAH  production  during  grilling
of meat).  The  mode  of  action  by  which  these  probiotics
lower the  risk  derived  from  ingested  hazardous  components
often relates  to  the  sorption  of  the  compound  to  micro-
bial biomass.  This  is  the  case  for  aﬂatoxin  B1,  for  example,
which has  been  shown  in  vitro  to  be  bound  by  probiotic
strains.58 Another  mode  of  action  may  be  direct  detoxiﬁ-
cation of  the  hazardous  compound,  such  as  the  breakdown
of fumonisin  by  Pediococcus  pentosaecus  L006  isolated  from
corn leaves.  A  ﬁnal  mode  of  action  is  more  indirect  and
a
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esembles  the  abovementioned  probiotic  modulation  of  gut
icroenvironment,  where  (food)  pathogens  produce  toxins.
or example,  the  production  of  organic  acids  by  probio-
ic microorganisms  was  reported  to  negatively  affect  the
roduction of  Shiga-toxin  2  from  enterohemorrhagic  E.  coli
157:H7.
mmunological  functionality
he  immunological  beneﬁts  of  probiotics  can  be  due  to
ctivation of  local  macrophages  and  modulation  of  IgA
roduction locally  and  systemically,  to  changes  in  pro/anti-
nﬂammatory cytokine  proﬁles,  or  to  the  modulation  of
esponse towards  food  antigens.59,60
robiotic  products  in  prevention  and  treatment
he  following  paragraphs  does  not  aim  to  provide  a  complete
verview of  all  indications  in  which  probiotics  have  been
tudied as  possible  preventive  and/or  therapeutic  interven-
ion, since  new  manuscripts  are  published  weekly.  Rather,
he authors  focused  on  the  most  relevant  indications  for
hildren.
cute  infectious  diarrhea
robiotics  have  been  largely  studied  for  the  prevention
f acute  infectious  diarrhea.  Large,  randomized  controlled
rials (RCT)  provide  evidence  of  a very  modest  effect  (statis-
ically signiﬁcant,  but  of  questionable  clinical  importance)
f some  probiotic  strains  (L.  rhamnosus  GG,  and  strains  of  L.
euteri and  Biﬁdobacterium  (B.)  animalis  subsp.  lactis)  on
he prevention  of  community-acquired  diarrhea.61--69 Many
andomized and  placebo-controlled  trials  conducted  in  dif-
erent parts  of  the  world  have  assessed  the  use  of  probiotics
or prevention  of  diarrhea  acquired  in  day-care  centers.  The
ain probiotics  tested  were  L.  rhamnosus  GG,  B.  animalis
ubsp. lactis  alone  or  in  combination  with  S.  thermophilus,
nd L.  reuteri,  L.  rhamnosus  (not  GG),  and  L.  acidophilus
ither alone  or  in  a comparative  study.  The  evidence  of  their
fﬁcacy in  these  settings  is  only  modest  for  the  prevention
f diarrhea  and  sometimes  also  for  preventing  upper  respira-
ory infections.66 However,  the  protective  effect  on  diarrhea
revention becomes  far  less  signiﬁcant  if  the  incidence  of
iarrhea (episodes  per  patient-month)  rather  than  the  per-
entage of  patients  with  diarrhea  is  taken  into  account.68
n  hospitalized  children,  the  administration  of  L.  reuteri
SM 17938  compared  with  placebo  had  no  effect  on  the
verall incidence  of  nosocomial  diarrhea,  including  rotavirus
nfection.70 Although  the  same  strain  prevented  diarrhea  in
reschool children,71 the  clinical  impact  of  such  ﬁndings  can
e  questioned.72
The  use  of  the  following  probiotics  (in  alphabetical  order)
ay be  considered  in  the  management  of  children  with
cute gastroenteritis  in  addition  to  rehydration  therapy:  L.
hamnosus GG  (low  quality  of  evidence;  strong  recommen-
ation) and  S.  boulardii  (low  quality  of  evidence;  strong
ecommendation). Less  compelling  evidence  is  available  for
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.  reuteri  DSM  17938  (very  low  quality  of  evidence;  weak
ecommendation) and  heat-inactivated  L.  acidophilus  LB
very  low  quality  of  evidence;  weak  recommendation).73 The
atter, although  traditionally  discussed  with  other  probio-
ics, does  not  ﬁt  in  the  deﬁnition  of  probiotics.  A  number
f RCTs  have  evaluated  the  effect  of  Enterococcus  fae-
ium SF6873.73 A  sub-group  analysis  performed  within  a
ochrane review  (search  date:  July  of  2010)  found  that
. faecium  SF68  reduced  the  risk  of  diarrhea  lasting  ≥
our days  (four  RCTs,  n  =  333;  RR:  0.21;  95%  CI:  0.08  to
.52).73 However,  in  vitro  studies  have  documented  that
he E.  faecium  SF68  strain  is  a  possible  recipient  of  van-
omycin resistance  genes.74 Considering  that  the  risk  for
n vivo  conjugation  cannot  be  discarded,  probiotics  with
afety issues  should  not  be  used.73 Recent  publications
ave strengthened  the  evidence  for  L.  reuteri  in  the
reatment of  diarrhea  in  hospitalized  children.75,76 Other
trains or  combinations  of  strains  have  been  tested,  but
vidence of  their  efﬁcacy  is  weak  or  preliminary.  Mix-
ures of  different  strains  do  not  necessarily  score  better.77
ince  in  tropical  countries  with  zinc-deﬁcient  regions,
inc is  now  added  to  oral  rehydration  salts  (ORS),  the
mpact of  probiotics  above  its  efﬁcacy  should  be  studied.77
onsidering  that  an  acute  gastroenteritis  will  heal  spon-
aneously in  almost  every  child,  the  cost/beneﬁt  impact
ill in  great  part  determine  whether  probiotics  should  be
sed.78,79
ntibiotic-associated  diarrhea  (AAD)
he  pooled  relative  risk  in  a  meta-analysis  of  63  RCTs,  which
ncluded 11,811  participants,  indicated  a  statistically  signif-
cant association  of  probiotic  administration  with  reduction
n AAD  (relative  risk,  0.58;  95%  CI,  0.50  to  0.68;  p  <  0.001;
(2), 54%;  [risk  difference,  -0.07;  95%  CI,  -0.10  to  -0.05],
NNT 13;  95%  CI,  10.3  to  19.1])80 Another  meta-analysis
oncluded the  NNT  was  8.81 According  to  a  recent  meta-
nalysis, probiotics  signiﬁcantly  reduce  the  risk  of  AAD  in
hildren.82 Preplanned  subgroup  analysis  showed  that  reduc-
ion of  the  risk  of  AAD  was  associated  with  the  use  of  L.
hamnosus GG  (95%  CI:  0.15  to  0.6),  S.  boulardii  (95%  CI:
.07-0.6), or  B.  lactis  and  S.  thermophilus  (95%  CI:  0.3  to
.95).82 For  every  seven  patients  that  would  develop  diar-
hea while  being  treated  with  antibiotics,  one  fewer  will
evelop AAD  if  also  receiving  probiotics82 Only  S.  boulardii
as reported  to  be  effective  in  C.  difﬁcile  disease.83--85
ecently,  a  large  single-center  study  showed  in  elderly  that
. boulardii  was  not  effective  in  preventing  the  develop-
ent of  AAD  or  in  prevention  of  C.  difﬁcile  infection.86 In
any studies,  there  is  no  evidence  to  support  the  use  of
ny (other)  probiotic  to  prevent  the  recurrence  of  C.  dif-
cile infection  or  to  treat  existing  C.  difﬁcile  diarrhea.64
 new  meta-analysis  concluded  that  probiotics  signiﬁcantly
educe the  incidence  of  pediatric  AAD  (22  trials;  RR  =  0.42;
5% CI:  0.33-0.53)  and  the  incidence  of  pediatric  C.  difﬁ-
ile infection  (ﬁve  trials;  RR  =  0.35;  95%  CI:  0.13-0.92).85 S.
oulardii  (RR  =  0.43;  95%  CI:  0.32-0.60)  and  L.  rhamnosus
G (RR  =  0.36;  95%  CI:  0.19-0.69)  are  the  two  best  studied
trains.87 In  most  studies,  the  probiotic  is  started  together
ith antibiotic  treatment.88
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raveler’s  diarrhea
raveler’s  diarrhea  is  a  frequent  condition  of  great  socio-
conomic impact.  In  this  topic,  there  are  more  reviews
han original  research  studies  published.  Different  RCTs  have
een performed  evaluating  the  efﬁcacy  of  probiotics  in  the
revention of  traveler’s  diarrhea.  One  trial  with  L.  aci-
ophilus and  two  with  L.  rhamnosus  GG  observed  negative
esults.89--91 One  trial  with  S.  boulardii  reported  a  small  but
igniﬁcant preventive  effect  in  a subgroup,  suggesting  geo-
raphical differences  in  efﬁcacy.92 In  a  review,  McFarland
oncluded that  there  is  comparable  evidence  for  efﬁcacy  for
. rhamnosus  GG,  L.  casei  DN-114001,  and  S.  boulardii,  and
o efﬁcacy  for  L.  acidophilus.93 Since  the  number  of  studies
n traveler’s  diarrhea  is  very  limited,  a  recent  meta-analysis
oncluded that  probiotics  are  not  efﬁcient  for  traveler’s
iarrhea.94 There  are  no  data  on  prebiotics  and  prevention
r treatment  of  traveler’s  diarrhea.  Overall,  the  number  of
tudies is  too  small  to  allow  for  recommendations.95
rritable  Bowel  Syndrome  (IBS)
here  is  substantial  literature  on  the  effect  of  probiotics  on
BS in  adults,  but  data  in  children  are  limited.  A  Cochrane
eview from  2009  failed  to  demonstrate  an  effect  of  ﬁber
upplements and  recorded  a  limited  effect  of  lactobacilli
n symptoms  compared  to  placebo  (OR:  1.17;  95%  CI:  0.62,
.21).96
A  RCT  of  six  weeks  with  L.  rhamnosus  GG  versus  placebo
howed overall  negative  results  in  50  children  and  young
dults, although  there  was  a  lower  incidence  of  perceived
bdominal distension  in  the  L.  rhamnosus  GG  group.97 L.
hamnosus GG,  but  not  placebo,  caused  a  signiﬁcant  reduc-
ion of  both  frequency  and  severity  of  abdominal  pain
ompared to  baseline,  and  inﬂuenced  intestinal  permeabil-
ty testing.98 A  meta-analysis  demonstrated  that,  compared
ith placebo,  L.  rhamnosus  GG  supplementation  was  associ-
ted with  a  signiﬁcantly  higher  rate  of  treatment  responders
n the  overall  population  with  abdominal  pain-related  func-
ional GI  disorders  and  in  the  IBS  subgroup.99 However,  no
ifference was  observed  in  children  with  functional  abdom-
nal pain  or  functional  dyspepsia  who  received  placebo  or
. rhamnosus  GG.  A  randomized  cross-over  trial  with  VSL#3
nd placebo,  comprising  59  patients  for  six  weeks,  with  a
wo-week washout  period  in-between,  showed  a  superior
ffect of  VSL#3  compared  to  placebo  in  symptom  relief,
s well  as  in  abdominal  pain/discomfort,  abdominal  bloat-
ng/gassiness, and  family  assessment  of  life  disruption.99 No
igniﬁcant difference  was  found  in  the  stool  pattern.100
There  are  no  data  on  prevention  or  treatment  of  IBS
ith prebiotics.  Data  from  one  trial  suggest  that,  in  infants,
 prebiotic-containing  whey-based  formula  provides  supe-
ior GI  comfort  than  a  control  formula.101 A peptide-based
ormula containing  ﬁber  was  as  well-tolerated  as  a  ﬁber-
ree formula  in  a  small  population  of  children  with  GI
mpairments.102 Extremes  of  stool  consistency  were  normal-
zed with  the  ﬁber  formula.  No  signiﬁcant  differences  were
bserved in  vomiting,  abdominal  pain,  feeding  intakes,  or
eight gain  between  the  two  formulas.103 Synbiotics  should
e further  investigated  in  this  indication.103 Probiotics  are
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more  effective  than  placebo  in  the  treatment  of  patients
with abdominal  pain-related  functional  gastro-intestinal  dis-
orders, especially  with  respect  to  patients  with  IBS.104
Helicobacter  pylori
The  use  of  probiotics  in  H.  pylori-colonized  subjects  with
gastric inﬂammation  is  supported  by  many  observations.
Speciﬁc strains  of  Lactobacillus  and  Biﬁdobacerium  exert
in vitro  bactericidal  effects  against  H.  pylori  through  the
release of  bacteriocins  or  production  of  organic  acids,
and/or inhibit  its  adhesion  to  epithelial  cells.  Such  protec-
tive effects  have  been  conﬁrmed  in  animal  models.  Clinical
trials are  very  important,  since  in  vitro  results  cannot  always
be reproduced  in  patients.  Probiotics  decrease  the  bacte-
rial load  and  improve  the  immune  response.105 Results  of
clinical trials  indicate  that  probiotics  generally  do  not  erad-
icate H.  pylori,  but  decrease  the  density  of  colonization,
thereby maintaining  lower  levels  of  this  pathogen  in  the
stomach; in  association  with  antibiotic  treatments,  some
probiotics increased  eradication  rates  and/or  decreased
adverse effects  due  to  the  antibiotics.  Many  studies  show
a moderate  higher  eradication  rate  (∼10%)  of  H.  pylori
when probiotics  are  added  to  the  antibiotics  and  proton
pump inhibitor.106 Although  L.  rhamnosus  GG  appears  not  to
improve eradication,107 most  probiotic  bacteria  and  yeasts
reduce the  adverse  effects  of  standard  H.  pylori  eradication
regimens.108,109 Probiotics  supplementation  in  triple  ther-
apy for  H.  pylori  infection  may  have  beneﬁcial  effects  on
eradication and  therapy-related  side  effects,  particularly
diarrhea, in  children.110
Constipation
Constipation  is  a  frequent  problem  in  childhood  in  which
pre- and  probiotics  could  have  a  positive  inﬂuence  on  the
intestinal microbiota  with  an  effect  on  stool  consistency
and frequency.  Unfortunately,  study  results  are  contradic-
tory. In  an  open  trial,  B.  breve  was  effective  in  increasing
stool frequency  in  children  with  functional  constipation.111
Furthermore,  it  had  a  positive  effect  regarding  improving
stool consistency,  decreasing  the  number  of  fecal  inconti-
nence episodes,  and  reducing  abdominal  pain.111 In  another
open trial,  a  probiotic  mixture  (Ecologic  Relief®,  Winclove
Pro Biotics,  Netherlands)  containing  B.  biﬁdum,  B.  infantis,
B. longum,  L.  casei,  L.  plantarum,  and  L.  rhamnosus  showed
positive effects  on  constipation  symptoms.112 L.  rhamno-
sus Lcr35  was  effective  in  treating  children  with  chronic
constipation.113 B.  lactis  was  reported  to  be  non  effective  for
constipation.94,114 L.  reuteri  DSM  17938  had  a  positive  effect
in infants  with  chronic  constipation  on  bowel  frequency,
even when  there  was  no  improvement  in  stool  consistency
and episodes  of  inconsolable  crying  episodes.115 A  Brazilian
study showed  a  positive  inﬂuence  of  yoghurt  on  stool  fre-
quency with  an  additional  effect  of  yoghurt  supplemented
with B.  longum.116 In  constipated  children,  a  fermented
dairy product  containing  B.  animalis  subsp.  lactis  DN-173
010 increase  stool  frequency,  but  this  increase  was  compa-
rable with  that  observed  in  the  control  group.117 There  is
e
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t13
urrently  not  sufﬁcient  evidence  to  recommend  fermented
airy products  containing  strain  DN-173  010  in  this  cate-
ory of  patients.117 No  evidence  for  any  effect  was  found
or ﬂuid  supplements,  prebiotics,  probiotics,  or  behavioral
ntervention.118 Probiotics  have  not  proven  effective  for
hildren with  functional  constipation.104 Until  more  data  are
vailable, the  use  of  probiotics  for  the  treatment  of  consti-
ation condition  should  be  considered  investigational.119
ecrotizing  enterocolitis
ecrotizing  enterocolitis  (NEC)  is  a  severe  condition  occur-
ing especially  in  preterm  infants.  Abnormal  GI  microbiota
evelopment has  been  hypothesized  as  one  of  the  possi-
le etiologic  factors.  The  ﬁrst  publication  reporting  that  L.
cidophilus and  B.  infantis  reduced  NEC  dates  back  from
999.120 This  was  followed  by  a  negative  study  showing  that
even days  of  L.  rhamnosus  GG  supplementation  starting
ith the  ﬁrst  feed  was  not  effective  in  reducing  the  inci-
ence of  urinary  tract  infection,  NEC  and  sepsis  in  preterm
nfants.121 Then,  several  randomized  trials  with  different
actobacilli and  biﬁdobacteria  showed  a signiﬁcant  reduc-
ion in  development  of  NEC.122,123 Although  S.  boulardii  was
hown to  ameliorate  hypoxia/reoxygenation-induced  NECs
n young  mice,124 it  did  not  protect  for  NEC  in  infants.125
 Cochrane  review  concluded  in  2008  that  enteral  probio-
ic supplementation  reduced  the  incidence  of  NEC  stage  II
r more  and  mortality.126 No  systemic  infections  or  serious
dverse events  were  directly  attributed  to  the  administered
robiotic microorganism.126 According  to  the  published  tri-
ls, the  NNT  to  prevent  one  case  of  NEC  is  21  and  27.126
owever,  the  centers  in  which  these  trails  have  been  per-
ormed have  a much  higher  incidence  of  NEC  than  most
uropean or  North  American  centers.  The  recommenda-
ion may  be  different  in  centers  with  a  high  incidence  of
EC, in  which  other  measurements  to  decrease  NEC  are  dif-
cult to  apply.  The  updated  Cochrane  review  from  2011
omes to  different  conclusions:  enteral  supplementation
f probiotics  prevents  severe  NEC  and  all  cause  mortal-
ty in  preterm  infants.127 The  updated  review  of  available
vidence supports  a  change  in  practice.  More  studies  are
eeded to  assess  efﬁcacy  in  extremely  low  birth  weight
nfants and  to  assess  the  most  effective  formulation  and
ose to  be  used.127 The  debate  regarding  whether  probiotics
hould be  systematically  given  to  preterms  is  still  ongoing.
he 2012  systematic  review  of  the  American  Pediatric  Sur-
ical Association  Outcomes  and  Clinical  Trials  Committee
cknowledges that  recent  Cochrane  reviews  support  the  use
f  prophylactic  probiotics  in  preterm  infants  weighing  less
han 2,500  g  to  reduce  the  incidence  of  NEC,  as  well  as  the
se of  human  breast  milk  rather  than  formula  when  possi-
le. There  is  no  clear  evidence  to  support  delayed  initiation
r slow  advancement  of  feeds.128 However,  an  expert  group
f nutritionists  and  neonatologists  concluded  that  there  is
nsufﬁcient evidence  to  recommend  the  routine  use  of  pro-
iotics to  decrease  NEC.129 According  to  this  group,  there  is
ncouraging data  to  justify  further  investigation  regarding
he efﬁcacy  and  safety  of  speciﬁc  probiotics  in  circum-
tances of  high  local  incidence  of  severe  NEC.129 According
o others,  available  evidence  is  still  too  limited  in  order  to
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ecommend  probiotics  to  reduce  NEC.130 A  third  group  sug-
ests that  it  may  become  unethical  not  to  give  probiotics  to
reterm babies  to  decrease  NEC.131 Enteral  supplementation
f probiotics  prevents  severe  NEC  and  all  cause  mortality  in
reterm infants.132
olic
olic  is  a  frequent  problem  in  infants  and  often  parents
re desperate  for  a  solution.  In  this  indication,  the  effect
f L.  reuteri  has  been  exhaustively  studied  in  breastfed
nfants.133--135 However,  recent  data  suggested  that  infants
iven the  same  probiotic  cry  for  50  minutes  more  than  those
iven placebo.136 Dupont  et  al.  reported  efﬁcacy  of  another
robiotic strain  in  formula  fed  infants.137 A  synbiotic  sachet
ontaining 1  billion  CFU  of  L.  casei,  L.  rhamnosus,  S.  ther-
ophilus, B.  breve,  L.  acidophilus,  B.infantis,  L.  delbrueckii
ubsp. bulgaricus,  and  fructooligosacharide  was  shown  to  be
ffective in  reducing  colic  in  breastfed  infants  when  com-
ared to  placebo.138
llergy  and  atopic  dermatitis
imultaneous  pro-  and  prebiotic  treatment  (a  mixture  of
our strains  and  GOS)  given  to  pregnant  women  for  two  to
our weeks  before  delivery  and  to  the  infants  for  six  months
howed no  effect  on  the  cumulative  incidence  of  allergic
iseases at  the  age  of  2  years  when  compared  with  placebo,
ut tended  to  reduce  IgE-associated  (atopic)  diseases  since
 signiﬁcant  reduction  of  (atopic)  eczema  was  noticed.139
owever,  Taylor  et  al  challenged  the  role  of  probiotics  in
llergy prevention,  observing  that  early  probiotic  supple-
entation with  L.  acidophilus  did  not  reduce  the  risk  of
topic dermatitis  (AD)  in  high-risk  infants,  and  was  even
ssociated with  increased  allergen  sensitization  in  infants
eceiving supplements.140 A  Cochrane  review  from  2007  con-
luded that  there  was  insufﬁcient  evidence  to  recommend
he addition  of  probiotics  to  infant  feeds  for  prevention  of
llergic disease  or  food  hypersensitivity.141 Although  there
as a  reduction  in  clinical  eczema  in  infants,  this  effect
as not  consistent  between  studies,  and  caution  was  advised
n view  of  methodological  concerns  regarding  the  included
tudies.142 However,  the  efﬁcacy  of  probiotic  intervention  to
educe atopic  dermatitis  and/or  allergic  disease  may  depend
n the  moment  of  intervention.  Preventive  administration
f probiotics  may  be  only  effective  if  given  during  preg-
ancy. Probiotics  given  to  unselected  mothers  reduced  the
umulative incidence  of  AD,  but  had  no  effect  on  atopic
ensitization.142 A  recent  meta-analysis  showed  that  the
dministration of  lactobacilli  during  pregnancy  prevented
topic eczema  in  children  aged  2  to  7  years.143 However,
 mixture  of  various  bacterial  strains  does  not  affect  the
evelopment of  atopic  eczema,  independent  of  whether
hey contain  lactobacilli  or  not.143 L.  rhamnosus  HN001  was
eported effective  against  eczema  in  the  ﬁrst  two  years  of
ife, persisting  to  age  4  years,  while  B.  animalis  subsp.  lactis
N019 had  no  effect.144 Therefore,  not  only  timing  of  admin-
stration appears  to  important,  but  also  strain  speciﬁcity.
owever, timing  of  administration  and  strain  speciﬁcity  were
p
c
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hen  again  contradicted  in  the  meta-analysis  by  Pelucchi
t al.,  supporting  a  moderate  role  of  probiotics  in  the
revention of  atopic  dermatitis  and  IgE-associated  atopic
ermatitis in  infants,  regardless  of  the  time  of  probiotic  use
pregnancy  or  early  life)  or  the  subject(s)  receiving  probio-
ics (mother,  child,  or  both).145 The  data  on  probiotics  and
llergy need  further  clariﬁcation,  because  data  are  some-
ow contradictory.  Geographical  or  genetic  differences  may
ave  a  detrimental  role,  especially  for  atopic  dermatitis.
Ninety  infants  with  atopic  dermatitis,  age  <  7  months,
ere randomized  to  receive  an  infant  formula  with  B.  breve
-16 V  and  a  mixture  of  short  chain  GOS  and  long  chain  FOS,
r the  same  formula  without  synbiotics  during  12  weeks.146
here  were  no  signiﬁcant  differences  between  the  synbiotic
nd the  placebo  group.146 The  same  group  showed  that  syn-
iotics prevent  asthma-like  symptoms  in  infants  with  AD.147
t  the  same  time,  another  group  reported  that  a  synbiotic
ombination of  L.  salivarius  plus  FOS  is  superior  to  the  prebi-
tic alone  for  treating  moderate  to  severe  childhood  AD.148
hile  some  studies  with  probiotics  as  a  treatment  for  AD
how a  beneﬁt,149 most  studies  are  negative.  No  beneﬁt  was
eported from  supplementation  with  B.  animalis  subsp.  lac-
is or  L.  paracasei  in  the  treatment  of  eczema,  when  given
s an  adjunct  to  basic  topical  treatment,  and  no  effect  on
he progression  of  allergic  disease  from  age  1  to  3  years  was
bserved.150 Most  reviews  conclude  that  probiotics  are  not
ffective in  reducing  atopic  dermatitis.  These  contradictory
esults suggest  strain  speciﬁcity  or  a  genetic  inﬂuence  on  the
fﬁcacy of  probiotics  in  children  with  atopic  dermatitis.  A
eview of  13  studies  of  probiotics  for  treating  established
czema did  not  show  convincing  evidence  of  a clinically
orthwhile beneﬁt.151 However,  according  to  a  recent  meta-
nalysis, the  overall  result  suggests  that  probiotics  could  be
n option  for  the  treatment  of  atopic  dermatitis,  especially
or moderate  to  severe  cases,  and  no  evidence  was  found
upporting the  beneﬁcial  role  of  probiotics  in  infants.152
xtra-intestinal  infections  and  other  effects
o  pediatric  studies  have  demonstrated  deﬁnite  beneﬁcial
ffects of  administering  probiotics  to  treat  extra-intestinal
nfections such  as  respiratory  tract  infections  or  otitis
edia.88,153 There  is  no  evidence  that  probiotics  decrease
xtra-intestinal infections.  There  is  some  evidence  that
ome lactobacilli  might  prevent  recurrent  urinary  tract
nfection in  women.  However,  data  in  children  are  lacking.
he same  is  true  for  recurrent  vulvovaginitis.  Sazawal  et  al.
howed that  prebiotic  and  probiotic  fortiﬁed  milk  prevented
orbidities among  children  in  a  community-based  RCT.154
Candidiasis  accounts  for  10%  to  20%  of  bloodstream
nfections in  pediatric  intensive  care  units  (PICUs)  and  a
igniﬁcant increase  in  morbidity,  mortality,  and  length  of
ospital stay.155 A  few  studies  have  demonstrated  that
robiotics are  able  to  prevent  Candida  outgrowth  and  col-
nization in  neonates,  whereas  their  role  in  preventing
nvasive candidiasis  in  such  patients  is  still  unclear.155Puriﬁed  phytases  from  B.  longum  subsp.  infantis  and  B.
seudocatenulatum reduced  the  contents  of  phytate  when
ompared to  control  samples  (untreated  or  treated  with  fun-
al phytase),  and  led  to  increased  levels  of  myo-inositol
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triphosphate.156 This  is  the  ﬁrst  example  of  the  applica-
tion of  puriﬁed  biﬁdobacterial  phytases  in  food  processing,
demonstrating the  potential  of  these  enzymes  to  be  used
in products  for  human  consumption.156 Lactic  acid  bacteria
improve the  synthesis  of  vitamins  B2,  B11  and  B12  and  have
the potential  strategies  to  increase  B-group  vitamin  content
in cereals-based  products.157 Vitamin-producing  L.  has  been
leading to  the  elaboration  of  novel  fermented  functional
foods.157
Pandemic  obesity  is  now  a  matter  of  interest  in  all  devel-
oped and  developing  countries.  Treatment  with  probiotics
selectively changes  the  composition  of  the  gut  microbiota
in favor  of  speciﬁc  genus  and  even  strains.  Few  intervention
studies with  probiotics  in  overweight  or  obese  individuals
have been  published  until  now,  and  mostly  focus  on  L.  or  B.
The administration  of  a  strain  of  L.  gasseri  in  obese  and  type
2 diabetic  patients  has  been  shown  to  decrease  fat  mass  (vis-
ceral and  subcutaneous)  and  body  mass  index.158 In  addition,
Andreasen et  al.  have  demonstrated  that  the  adminis-
tration of  Lactobacillus  spp.  positively  impact  on  insulin
sensitivity.159 Compelling  evidence  suggests  that  early  gut
microbiota modulation  with  probiotics  reduces  the  body
mass index  in  young  children  by  restraining  excessive  weight
gain during  the  ﬁrst  years  of  life  (from  0  to  10  years  of  follow-
up).160 So  far,  only  few  data  are  available  on  the  possible
application of  lactobacilli  or  biﬁdobacteria  to  counteract
adiposity.
Fecal  microbiota  transplantation
A  new  approach  in  microbial  therapeutic  applications  is
transplantation of  intestinal  microbiota,  especially  in  dif-
ﬁcult to  treat  conditions  in  which  it  is  known  that  the
fecal microbiota  is  abnormal.161,162 Observed  side  effects
warrant caution  in  the  ongoing  pursuit  of  this  treatment
option.162 There  is  evidence  that  many  diseases  are  related
to intestinal  dysbiosis.  As  a  consequence,  manipulation  of
the intestinal  microbiota  is  a  very  attractive  therapeutic
approach. However,  results  are  often  negative,162 although
positive results  have  been  reported.163 The  transplanted
microbiota should  be  carefully  screened  for  pathogens.164
Bacteremia  has  been  reported  as  an  adverse  event.165
However,  the  ﬁrst  cure  of  early  onset  colitis  after  fecal
microbiota transplantation  has  been  reported.166 Further
studies should  now  focus  on  the  reasons  for  success  and
failure.
Safety  and  side  effects
Probiotics  have  a  long  record  of  safety,  which  relates
primarily to  the  use  of  lactobacilli  and  biﬁdobacteria.167
Experience  with  other  microorganisms  used  as  probiotic  is
more limited.  There  is  no  such  thing  as  zero  risk,  particu-
larly in  the  context  of  certain  forms  of  host  susceptibility.167
Probiotics  are  generally  regarded  as  safe,  and  side  effects
in ambulatory  care  have  almost  not  been  reported.  Large
scale epidemiological  studies  in  countries  where  probiotic
use is  endemic  demonstrate  (in  adults)  low  rates  of  sys-
temic infection,  between  0.05  and  0.40%.168 Administration15
uring  pregnancy  and  early  infancy  is  considered  safe.169
robiotic  compounds  may  contain  hidden  allergens  of  food
nd may  not  be  safe  for  subjects  with  allergy  to  cow’s
ilk or  hen’s  eggs.170 Documented  invasive  infections  have
een primarily  noted  to  occur  in  immunocompromised
dults, but  invasive  infections  in  infants  and  children  are
xtremely rare.171--173 Two  cases  of  bacteremia  attributable
o Lactobacillus  supplementation  with  genotypically  identi-
al clinical  and  supplement  isolates  were  recently  reported
n an  infant  and  a  child  without  underlying  GI  disease  or
mmunocompromised status.174 Sepsis  with  probiotic  lac-
obacilli has  been  reported  in  children  with  short  gut.
ecently, plasmid  transfer  of  antibiotic  resistance  has  been
hown to  be  clinically  possible.  Long-term  use  of  probiotics
nder antibiotic  selection  pressure  could  cause  antibiotic
esistance, and  the  resistance  gene  could  be  transferred  to
ther bacteria.175 Translocation  from  the  gastro-intestinal
ract into  the  systemic  circulation  has  not  been  reported.
here is  poor  public  understanding  of  the  concept  of  risk,  in
eneral, and  risk/beneﬁt  analysis,  in  particular.168 Uncer-
ainty regarding  the  potential  for  transfer  of  antibiotic
esistance with  probiotics  persists,  but  the  risk  appears  to  be
ow with  currently  available  probiotic  products.168 As  with
ther forms  of  therapeutics,  the  safety  of  probiotics  should
e considered  on  a  strain-by-strain  basis.168 The  potential
eneﬁts of  supplementation  should  be  weighed  against  the
isk of  development  of  an  invasive  infection  resulting  from
robiotic therapy.
onclusion
robiotics  have  entered  the  mainstream  of  healthcare.  The
astro-intestinal microbiota  is  fundamental  for  the  develop-
ent of  the  immune  system.  Although  the  main  indications
f the  medical  use  of  probiotics  is  still  in  the  area  of
he prevention  and  treatment  of  gastro-intestinal  related
isorders, gradually  more  evidence  is  collected  on  extra-
ntestinal indications,  such  as  vaginitis,  atopic  dermatitis,
nd respiratory  tract  infections.  Randomized  controlled  tri-
ls with  commercially  available  products  in  the  claimed
ndications are  mandatory  before  their  use  can  be  recom-
ended. Currently,  L.  rhamnosus  GG  and  S.  boulardii  are  the
est-studied strains,  while  recent  literature  provides  posi-
ive data  on  L.  reuteri.  Although  adverse  effects  have  been
poradically reported,  probiotics  can  be  considered  safe.
isuse and  use  of  products  that  have  not  been  validated
ay constitute  potential  drawbacks.
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